Nexgel Inc
NASDAQ:NXGL
Nexgel Inc
NexGel, Inc. engages in the manufacture of polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company is headquartered in Langhorne, Pennsylvania. The company went IPO on 2021-12-22. The firm is engaged in the manufactures of high-water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. The firm specializes in custom gels by capitalizing on manufacturing technologies. Its products are manufactured by using proprietary and non-proprietary mixing, coating and cross-linking technologies. The company operates as a contract manufacturer of aqueous polymer hydrogels. The company delivers medication through hydrogel patches. Its Hydrogel patches are used for transdermal applications, such as hormone replacement therapy and contraception, treatment of acne, shingles, diabetes, motion sickness, treatment of angina with nitroglycerin and treatment of smoking addiction.
NexGel, Inc. engages in the manufacture of polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company is headquartered in Langhorne, Pennsylvania. The company went IPO on 2021-12-22. The firm is engaged in the manufactures of high-water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. The firm specializes in custom gels by capitalizing on manufacturing technologies. Its products are manufactured by using proprietary and non-proprietary mixing, coating and cross-linking technologies. The company operates as a contract manufacturer of aqueous polymer hydrogels. The company delivers medication through hydrogel patches. Its Hydrogel patches are used for transdermal applications, such as hormone replacement therapy and contraception, treatment of acne, shingles, diabetes, motion sickness, treatment of angina with nitroglycerin and treatment of smoking addiction.
Revenue: NEXGEL reported third quarter revenue of $2.9 million, flat year-over-year and slightly higher sequentially.
Margins: Gross profit margin improved to 42.4% from 39.3% last year, reflecting operational efficiencies.
EBITDA Loss: Adjusted EBITDA loss narrowed to $354,000 in Q3, continuing a positive trend from previous quarters.
Guidance: Full-year 2025 revenue is expected between $12 million and $12.5 million, with Q4 projected to be a record quarter.
Contract Manufacturing: Strong growth from existing customers and new partnerships such as iRhythm; new customer pipeline remains robust.
Consumer Products: Product launches delayed by logistical issues but resolved; strong holiday quarter expected.
Cash Position: Company maintains a solid cash balance, aided by $1 million non-dilutive funding from STADA.
